‹ Browse★ Saved
🏥 Health & Medicine
Insmed
(INSM ↗)
insmed.com ↗
Insmed develops drugs for serious, rare lung diseases. It already sells one (Arikayce) and just launched a second (Brinsupri) that's tripling its revenue — while still losing over a billion dollars a year funding research and the launch. A biotech right at the moment its science turns into a business.
Updated · Q1 2026 · March 2026
6
Chapters
~13
Min read
$820M / yr revenue · public since 2000
🌶️🌶️🌶️🌶️
Spice: Ghost (5/5)
More filled = spicier (more aggressive), not "better." Tap a row to see what it means.
What is spice?
Your progress
0 of 6
1
Growth
~3 min
The Moment Science Becomes a Business
Insmed's revenue more than tripled in a single year. That's what it looks like when a biotech's new drug finally reaches patients.
›
2
Financial Health
~2 min
A Billion-Dollar Bet, Up Front
Insmed lost $1.25 billion in 2025 — twice its revenue. In biotech, that spending is the product.
›
3
Moat
~2 min
Approved Drugs Are the Moat
Insmed's moat isn't a brand or a factory. It's a small number of approved drugs, protected by patents and years of trial data nobody can shortcut.
›
4
Management
~2 min
Proven It Can Get Drugs Approved
The hardest thing in biotech is turning a lab idea into an approved, selling drug. Insmed's management has now done it twice.
›
5
Behind the Numbers
~2 min
The Story Behind the Numbers
The income statement says *what* happened. The company's own write-up says *why*.
›
6
Risk
~2 min
Riding a Launch, Betting on a Few Drugs
Insmed has the best problem in biotech — a launch that's working. It also has biotech's eternal risk: almost everything rides on a handful of products.
↻ Next update · Aug 7
est. Aug 7, 2026 · Q2 2026 · Insmed Investor Relations ↗
›
✦ Reader takes on Insmed
0 comments
Drop your read. See how others are calling this brief.
No one's weighed in yet. Be the first.
↗ Share Insmed
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time Insmed files a new report, the chapters get updated here.